Back To TOP

Co-pay Cards Genentech BioOncology™ Co-pay Card

PERJETA Access Solutions offers the Genentech BioOncology Co-pay Card to help you with the out-of-pocket costs of your PERJETA® (pertuzumab) prescription.

activate card

 

 

Qualified Patients*

  • I am covered by commercial insurance

    - To answer "yes" to this question, you cannot be covered by a government-funded health care program such as Medicare, Medicaid, Medigap, VA, DoD or Tricare

  • I am age 18 years or older
  • I currently live or get treatment in the United States or Puerto Rico†

 

If you answered "yes" to all the questions above, you are eligible.

 

* If you are receiving funding from the Genentech® Access to Care Foundation, you are not eligible for the Genentech BioOncology Co‐pay Card.
† Vermont state laws do not allow programs like this.

 

 

What the card covers

 

 

Need help with enrollment? Call (855) MYCOPAY/(855) 692-6729.

FAQs

 
Q:

What types of help do you offer when my plan asks for high co-pays?

 
A: 

If you have concerns about covering the cost of your co-pay, we can help. We can refer you to a co-pay foundation to assist you. It can help you cover the cost of the co-pay. We also offer a co-pay card program.

 
View All

Learn More About
PERJETA
  • LEARN about treatment with PERJETA
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for PERJETA
  • Form Patient Authorization and Notice of Release of Information (Current Version)

What does PERJETA treat?

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel (chemotherapy) in people with HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

  • Most Serious Side Effect: Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects

- If you think you may be pregnant, you should contact your healthcare provider immediately

- If you are exposed to PERJETA during pregnancy, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720

  • Other possible serious side effects of PERJETA therapy include:

- Heart problems

- Infusion-related reactions

- Severe allergic reactions (hypersensitivity reactions/anaphylaxis)

  • PERJETA has been shown to work only in people with HER2-positive breast cancer
  • The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) are:

- Diarrhea

- Hair loss

- Low levels of white blood cells with or without a fever

- Nausea

- Feeling tired

- Rash

- Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech or the FDA. You may report side effects to the FDA at 1-800-FDA­‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see PERJETA full Prescribing Information including Most Serious Side Effect for additional Important Safety Information.